Share on StockTwits

Cardinal Health (NYSE:CAH) CEO Michael C. Kaufmann sold 6,833 shares of the company’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $72.06, for a total value of $492,385.98. Following the completion of the sale, the chief executive officer now directly owns 118,576 shares in the company, valued at approximately $8,544,587. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Cardinal Health (NYSE:CAH) traded up 1.19% on Thursday, hitting $73.34. The stock had a trading volume of 880,880 shares. Cardinal Health has a 52 week low of $49.65 and a 52 week high of $74.40. The stock’s 50-day moving average is $71.18 and its 200-day moving average is $69.61. The company has a market cap of $24.690 billion and a price-to-earnings ratio of 21.45.

Cardinal Health (NYSE:CAH) last announced its earnings results on Monday, August 4th. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.02. The company had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $21.88 billion. During the same quarter in the previous year, the company posted $0.79 earnings per share. The company’s revenue for the quarter was down 9.9% on a year-over-year basis. On average, analysts predict that Cardinal Health will post $4.25 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Wednesday, October 15th. Stockholders of record on Wednesday, October 1st will be given a dividend of $0.3425 per share. This represents a $1.37 dividend on an annualized basis and a yield of 1.89%. The ex-dividend date of this dividend is Monday, September 29th.

A number of analysts have recently weighed in on CAH shares. Analysts at Argus reiterated a “buy” rating on shares of Cardinal Health in a research note on Monday. They now have a $71.43 price target on the stock, down previously from $83.00. Separately, analysts at Barclays reiterated an “overweight” rating on shares of Cardinal Health in a research note on Tuesday, August 5th. They now have a $82.00 price target on the stock, up previously from $77.00. Finally, analysts at Credit Suisse reiterated an “outperform” rating on shares of Cardinal Health in a research note on Tuesday, August 5th. They now have a $80.00 price target on the stock, up previously from $76.00. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $77.93.

Cardinal Health, Inc is a healthcare services company providing pharmaceutical and medical products and services to pharmacies, hospitals, ambulatory surgery centers, clinical laboratories, physician offices and other healthcare providers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.